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Abstract 
Background. Catheter ablation of atrial fibrillation (AFCA) is an established therapeutic option for 
rhythm control in symptomatic patients. Its efficacy and safety among patients with left ventricular 
systolic dysfunction is based on small populations, and data concerning long-term outcome are 
limited. We performed this meta-analysis to assess safety and long-term outcome of AFCA in 
patients with left ventricular systolic dysfunction, to evaluate predictors of recurrence and impact on 
left ventricular function. 
Methods and Results. A systematic review was conducted in MEDLINE/PubMed and Cochrane 
Library. Randomized controlled trials, clinical trials and observational studies including patients 
with left ventricular systolic dysfunction undergoing AFCA were included. Twenty-six studies were 
selected, including 1,838 patients. Mean follow-up was 23 (95% Confidence Interval: 18-40) 
months. Overall complication rate was 4.2 (3.6-4.8)%.  Efficacy in maintaining sinus rhythm at 
follow-up end was 60 (54-67)%. Meta-regression analysis revealed that time since first AF 
(p=0.030) and  heart failure (p=0.045) diagnosis related to higher, while absence of known 
structural heart disease (p=0.003) to lower incidence of AF recurrences. Left ventricular ejection 
fraction improved significantly during follow-up by 13% (p<0.001), with a significant reduction of 
patients presenting an ejection fraction <35% (p<0.001). NT-proBNP blood levels decreased by 620 
pg/ml (p<0.001). 
Conclusions. AFCA efficacy in patients with impaired left ventricular systolic function improves  
when performed early in the natural history of AF and heart failure. AFCA provides long-term 
benefits on left ventricular function, significantly reducing the number of patients with severely 
impaired systolic function.  
Abstract word count:    239 
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Introduction 
Catheter ablation of atrial fibrillation (AFCA) is a well-established and growing treatment option 
for patients with symptomatic atrial fibrillation (AF) refractory to antiarrhythmic drugs1. In fact, 
despite a relatively high incidence of late recurrences, the long-term efficacy in maintaining sinus 
rhythm (SR) remains encouragingly high, especially if compared to pharmacologic approaches2.  
AFCA has shown satisfactory safety and efficacy even in patients with moderate-severe structural 
heart disease and impaired left ventricular (LV) systolic function, with SR maintenance rates 
comparable to those of patients with normal LV function, although redo ablation procedures are 
more commonly required3,4. However these outcome data are based on small observational studies 
and no conclusive indication for AFCA in patients with reduced LV ejection fraction (LVEF) has 
been agreed.  
Therefore, the present systematic review and meta-analysis aims to investigate long-term outcome 
of AFCA in patients with reduced LVEF, focusing on procedural safety, rhythm control efficacy, 
predictors of recurrence and their impact on LV function. 
 
Methods 
The present study was conducted in accordance to current guidelines, including the recent Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) amendment to the Quality 
of Reporting of Meta-analyses (QUOROM) statement, as well as recommendations from The 
Cochrane Collaboration and Meta-analysis Of Observational Studies in Epidemiology (MOOSE)5,6. 
Search strategy and study selection 
MEDLINE/PubMed and Cochrane database were searched for pertinent articles published in 
English from 2002 until October 2013. Details on search strategy and terms, results selection and 
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data extraction are provided in the Supplemental Methods. Of note, 13 (50%) studies did not 
differentiate persistent and long-standing persistent AF. 
Statistical analysis 
Continuous variables were reported as mean (standard deviation) or median (range), and categorical 
variables as n (%), weighted for sample size of each study and according to standard error by 
logarithmic transformation. Funnel plot analysis was used to evaluate potential publication bias, and 
Cochran Q2 tests and I2 to investigate heterogeneity. Using rates of event as dependent variables, a 
meta-regression analysis was performed to test whether an interaction between incidence of AF 
recurrences and time since first AF and heart failure diagnosis, absence of known structural heart 
disease and AFCA protocol was present. Due to the observational design of most of the included 
studies, random effect was performed for all analysis. Statistical analyses were performed with 
Comprehensive Metanalysis (Trial Version) and Review Manager. 
 
Results 
Search results are summarized in Figure 1 and described in details in the Supplemental Results.  
Fifteen studies7-21 meeting the pre-specified inclusion criteria, and 11 long-term (at least 2 years) 
AFCA studies22-32, for which the corresponding Author was contacted and agreed to participate, 
were eventually included. 
First Author, study design, publication date and main characteristics of each included study are 
reported in  Supplemental Table 1 (Supplemental Material). 
Baseline patients characteristics 
A total of 1,838 patients were finally included from 26 studies. Baseline characteristics, derived 
combining confidence intervals from all studies, are shown in Table 1. The mean age from each 
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study ranged from 51 to 61 years and 38% were women. Paroxysmal AF accounted for 45% of the 
population. The mean LVEF ranged from 35% to 46% (mean value 40%) while mean left atrial 
antero-posterior diameter was 59 mm. LV systolic dysfunction was idiopathic in 39% of the 
patients, while coronary artery disease was the most common aetiology of LV impairment. The 
majority of patients were symptomatic from heart failure, with only 20% in NYHA class I at 
baseline. The time since first AF and heart failure diagnosis ranged from 29 to 46 and 20 to 28 
months, respectively. Basal pro-BNP levels were heterogeneously elevated ranging from 678 to 
1,400 pg/ml. 
Catheter ablation protocols and complications 
AFCA procedural characteristics are reported in Table 2. All patients underwent pulmonary veins 
(PV) isolation, while 45% and 54% of the patients were treated with additional linear lesions or 
focal ablation of complex fractioned atrial electrograms (CFAE) in the left atrium at first or redo 
procedure, respectively. Major procedural complications rate ranged from 3.6 to 4.8% (mean 4.2%; 
Figure 2). The most frequent complications were related to the access site and to cerebral 
thromboembolic events. Redo procedures were performed in 32 (24-36)% of the cases.  
Follow-up and recurrences 
Mean follow-up was 23 months, ranging from 18 to 40 months. Recurrences were defined, 
consistently within all the studies, as episodes of AF or atrial tachycardia or atypical atrial flutter 
lasting at least 30 seconds detected during follow-up (eTable 1), with a blanking period of 3 months 
after ablation. Overall AFCA long-term efficacy at the end of follow-up period was 60 (54-67)%. 
Efficacy after a single procedure ranged, instead, from 36% to 44% (mean value 40%; Figure 2). 
As shown in Figure 3, mean LVEF improved from 40 to 53% during follow-up, with a significant  
reduction of patients presenting an LVEF lower than 35% (p<0.001). Moreover, NT-proBNP levels 
decreased from 1,187 pg/ml before ablation to 567 pg/ml at follow-up end (p<0.001). 
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At meta-regression analysis (Figure 4), performed to test whether an interaction between relevant 
baseline clinical features2,33 and incidence of AF recurrence was present, time since first AF and 
heart failure diagnosis related to a higher recurrence rate, while absence of known structural heart 
disease was associated to a lower recurrence rate of AF. A PV isolation alone approach versus an 
AFCA with extensive left atrial ablation (additional linear lesions or CFAE) did not relate to higher 
SR long-term maintenance. 
 
Discussion 
The efficacy and safety of AFCA in patients with LV systolic dysfunction is based on small 
observational studies or meta-analyses that largely comprise a maximum of 500 patients. Through 
contacting each corresponding author of published long-term AFCA experiences in search of 
quantitative details on patients with impaired LV function, the present is the first study, to the best 
of our knowledge, to include a substantial number of patients with LV systolic dysfunction 
undergoing AFCA. In addition, the outcomes presented are based on long-term retrieved data 
specific to only those patients impaired LV systolic function. 
Based on the present analysis, overall complication rate of AFCA in patients with reduced LVEF  
was of  4.2 (3.6-4.8)%, a safety profile similar to that reported amongst the general AFCA 
population2,34. Indeed the AFCA in more complex and frail anatomical substrate, secondary to the 
LV dysfunction and elevated left chambers filling pressure, has been in previous single center 
studies related to higher complication rates17; however, a clear excess of undesirable events has not 
emerged in the present large multicenter real-world population. 
In the present analysis, first procedure efficacy was relatively low (40%), a finding reflective of the 
complexity of arrhythmia substrate in patients with reduced LVEF. However, with inclusion of 
repeat procedures the long-term AFCA efficacy improved to 60%, which is comparable to long-
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term outcomes reported from general AFCA populations2,26. Of note, based on meta-regression 
analysis, performing AFCA early in the natural history of the disease significantly improves 
outcome. This finding is consistent with recent data that suggest increasing time from initial ECG 
diagnosis of AF to ablation significantly increased risk of AF recurrence after AFCA, independently 
of the AF subtype35. We anticipate the delays in rhythm treatment may be augmented in patients 
with LV dysfunction, as AF and heart failure share many strong pathophysiologic links that 
mutually influence atrial fibrosis, anatomical and electrical remodeling36.  
The AFCA protocol used for the patients included in the present study was PV isolation alone in 
55% and 46% of the cases at first and redo procedure, respectively. In patients with reduced LV 
systolic function, especially in case of persistent AF, previous literature has shown that, due to 
complex atrial substrate sustaining multiple reentry circuits, PV isolation ablation protocols may not 
be optimal37,38. As such, an upfront strategy of PV isolation alone in the majority of patients with 
LV dysfunction may have impacted the long-term success rates and need for redo procedures. 
However, if ablation approaches evolve to consistently obtain transmural PV isolation during the 
initial procedure, additional substrate modification or linear ablation may not be requisite39. Further, 
linear lesions and ablation of CFAE deemed beneficial for substrate modification may increase risk 
of iatrogenic atypical atrial flutters or atrial tachycardias, if they are incomplete or not anchored to 
electrically inert structures40. As such the consequences of these recurrences may counterbalance 
the benefit derived by more aggressive atrial substrate modification. In fact, based on meta-
regression analysis, the AFCA protocol did not significantly relate to long-term outcome.  
An interesting finding was that all the studies included in the present analysis consistently reported 
improvement in LV function during the follow-up period. Other studies have also demonstrated a 
benefit in LV function after AFCA even in presence of preserved LV function41. These findings 
highlight the role of atrial contraction in preserving normal hemodynamic function. In addition, 
39% of the population did not present a known aetiology of their structural heart disease, therefore 
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LV function improvement could partially be explained by inclusion of patients with LV dysfunction 
secondary only to uncontrolled ventricular response (tachycardiomyopathy). However, recent 
randomized data suggest a similar improvement in LV function with definitive restoration of SR by 
AFCA, with little if any effect by increasing rate control13,21. Since AFCA is recommended only in 
case of rate and pharmacological rhythm control strategies failure, the incidence of real isolated 
tachycardiomyopathies should, therefore, be limited. Also, removal of long-term antiarrhythmic 
drug therapy when AFCA is successful, which often has a negative inotropic effect, may also 
provide pervasive benefit on LV function. Consistent with improvements in cardiac function over 
time, NT-proBNP levels declined significantly during follow-up after AFCA. NT-proBNP 
reduction has shown, after effective AFCA, to relate to favorable atrial remodeling and reduction in 
left atrial wall stress42. These findings are also applicable to those patients with severe disease. 
During the long-term follow-up, the number of patients with an LVEF lower than 35% significantly 
decreased. Patients with severe LV dysfunction are the most vulnerable to morbidity, mortality, and 
proarrhythmia from the majority of antiarrhythmic drugs for rhythm control43. As such, the 
pharmacologic options for these patients are often very limited, which translates to a direct need of 
nonpharmacologic options such as AFCA to improve long-term quality of life, morbidity and 
mortality associated in patients with coexistent AF and heart failure. Moreover, given current 
guideline recommendations for invasive treatments such as implantable defibrillators or cardiac 
resynchronization therapy, an LVEF improvement above 35% has relevant implications in terms of 
potentially reducing unnecessary device implantations, leading to a more focused patient selection 
and allocation of resources. 
 
Limitations 
This study presents the following limitations. First, AFCA is a relatively recent and developing 
procedure, with different centers using different protocols and tools. AFCA procedural 
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characteristics may grow heterogeneity, and influence safety and efficacy outcomes. Second, 
prevalence of patients with long-standing persistent AF is low; the AFCA outcome reported in this 
study may therefore be scarcely reflective of this subgroup of patients. Third, although 
heterogeneity was appraised by random effect, this meta-analysis, in order to include the largest 
amount of data available from current literature, combines randomized controlled trials with 
observational studies. The enrolled population may therefore be affected by selection bias of single 
centers’ experience and preference in referring patients to AFCA, excluding patients with heart 
failure considered unlikely to benefit from the procedure.. Finally, meta-regression analysis does 
not allow clinicians to drive causative inferences, but only speculative; large prospective 
multicenter clinical trials are needed to define AFCA safety and efficacy in this group of patients. 
 
Conclusion 
. AFCA long-term SR maintenance in patients with impaired LV systolic function is comparable to 
that reported on the long-term among the general population, especially when AFCA is performed 
early in the natural history of AF and heart failure. Moreover, LV function consistently improves 
over the follow-up, significantly reducing the proportion of patients with severely impaired LV 
systolic function. Large prospective multicenter trials are advised to clearly define the true safety 
and efficacy of AFCA in this subset population. 
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Table 1. Clinical features of patients included in the selected studies (1,838 patients).  
 Mean value  
 (Lower-Upper 95%Confidence Interval) 
Age, years 59 (51-61) 
Female gender, % 38 (29-43) 
BMI, kg/m2 29 (24-31) 
Mean follow-up, months 23 (18-41) 
Type of AF 
- Paroxysmal, % 
- Persistent, % 
- Long-standing persistent, % 
 
45 (41-56) 
50 (35-54) 
5.0 (2.0-7.0) 
Time since first AF diagnosis, 
months 
42 (29-46) 
Hypertension, % 63 (57-68) 
Diabetes mellitus, % 12 (9.0-15) 
Prior stroke/TIA, % 13 (11-19) 
Time since first heart failure 
diagnosis, months 
27 (20-28) 
Basal 6 minute walking test, 
meters 
534 (250-670) 
Basal pro-BNP (pg/ml) 11,187 (678-11,400) 
Thyroid disease 
- Hyperthyroidism, % 
- Hypothyroidism, % 
 
7.5 (5.5-8.5) 
3.5 (3.0-5.0) 
Chronic lung disease, % 5.0 (1.0-10) 
Obstructive sleep apnea, % 15 (7.5-19) 
NYHA class 
- I, % 
- II, % 
- III or IV, % 
 
20 (15-25) 
45 (35-49) 
35 (30-45) 
Cardiomiopathy 
- Ischemic, % 
- Hypertensive, % 
 
41 (35-46) 
10 (5.0-14) 
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- Valvular heart disease, % 
- Idiopathic, % 
10 (6.0-15) 
39 (35-45) 
QRS duration at ECG, msec 83 (80-120) 
Baseline medical therapy 
- Amiodarone, % 
- Oral anticoagulants, % 
- Beta-blockers, % 
 
33 (25-40) 
56 (45-69) 
70 (43-82) 
LVEF, % 
Left atrial AP diameter, mm 
40 (35-46) 
59 (40-110) 
 
BMI: body mass index; AF: atrial fibrillation. TIA: transient ischemic attack; NYHA: New York 
Heart Association; LVEF: left ventricular ejection fraction; AP: antero-posterior. 
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Table 2. Procedural features and efficacy rates of atrial fibrillation catheter ablation in the selected 
studies (1,838 patients).  
 Mean value  
(Lower-Upper 95% Confidence Interval) 
First procedure 
PV isolation, % 100 (100-100) 
PV isolation alone, % 55 (51-76) 
Left isthmus line, % 35 (10-50) 
Roof line, % 46 (34-48) 
CFAE, % 5.0 (1.0-7.0) 
Fluroscopy time, minutes 39 (24-64) 
Procedural time, hours 3.1 (2.6-3.8) 
Post procedural cardioversion, % 53 (30-65) 
Overall complications, % 4.2 (3.6-4.8) 
Access site complications, % 2.0 (1.0-2.5) 
Stroke/TIA, % 1.0 (0.6-1.5) 
Cardiac tamponade, % 1.2 (0.6-1.5) 
Others, % 1.2 (0.7-1.6) 
Redo procedures, 32 (24-36)% of patients 
Time after first procedure, months 12 (9.0-15) 
PV isolation, % 100 (100-100) 
PV isolation alone, % 46 (43-56) 
Left isthmus line, % 25 (21-29) 
Roof line, % 35 (31-34) 
CFAE, % 5.0 (1.0-7.0) 
First procedure efficacy, % 
Final efficacy, % 
40 (36-44) 
60 (54-67) 
 
PV: pulmonary veins; CFAE: complex fractioned atrial electrograms; TIA: transient ischemic 
attack.
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Figure 1. Search criteria and flow chart of the studies screened and included in the systematic 
review.  
 
LV: left ventricular. AF: atrial fibrillation.
23 
Figure 2. Funnel plot of the included studies concerning complication rates (A) and efficacy after first procedure (B) or at follow-up end (C). 
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Figure 3. Improvement of instrumental (echocardiographic and laboratory) parameters after atrial fibrillation catheter ablation.  
 
EF: left ventricular ejection fraction. 
25 
 
 
Figure 4. Meta regression analysis assessing the impact of time since first AF diagnosis (A, Beta 1.1: p=0.030), time since first heart failure 
diagnosis (B, Beta 0.67: p=0.045), absence of known structural heart disease (C, Beta -0.02: p=0.003), and other AFCA strategies than pulmonary 
veins isolation (D, Beta -0.023: p=0.340) on long-term incidence of AF recurrences.  
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AF: atrial fibrillation. AFCA: atrial fibrillation catheter ablation. 
